16 results
8-K
EX-10.1
SLRN
Acelyrin Inc
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
as independent shadow counsel for Employee and to represent Employee in the event of any conflict of interest or potential conflict of interest arising
10-K
2023 FY
SLRN
Acelyrin Inc
28 Mar 24
Annual report
4:21pm
investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA may therefore question the integrity
10-Q
1hid1798ahsvnz3
15 Jun 23
Quarterly report
4:19pm
8-K
EX-3.2
hv9da dcey
9 May 23
ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:16pm
424B4
rlpb6rlldnp43wqnqi
5 May 23
Prospectus supplement with pricing info
4:22pm
S-1/A
EX-10.11
lfk 6wzq3lp6
1 May 23
IPO registration (amended)
6:10am
S-1/A
4cycr0jrqv
1 May 23
IPO registration (amended)
6:10am
S-1/A
EX-10.10
egyrdi68v5
1 May 23
IPO registration (amended)
6:10am
S-1/A
EX-3.4
08c4sevrq8k4o
1 May 23
IPO registration (amended)
6:10am
S-1
EX-10.13
mqr1q9xpw3x5nqjh9
13 Apr 23
IPO registration
5:10pm
S-1
EX-2.1
2bnogtotgnuv29 th
13 Apr 23
IPO registration
5:10pm
S-1
y4t49
13 Apr 23
IPO registration
5:10pm
- Prev
- 1
- Next